A carregar...
A Scientific Rationale for Using Cystic Fibrosis Transmembrane Conductance Regulator Therapeutics in COVID-19 Patients
Several pathological manifestations in coronavirus disease 2019 (COVID-19), including thick mucus, poor mucociliary clearance, and bronchial wall thickening, overlap with cystic fibrosis disease patterns and may be indicative of “acquired” cystic fibrosis transmembrane conductance regulator (CFTR) d...
Na minha lista:
| Publicado no: | Front Physiol |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7672116/ https://ncbi.nlm.nih.gov/pubmed/33250777 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphys.2020.583862 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|